Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.

Saved in:
Bibliographic Details
Title: Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.
Authors: Thomas-Rüddel D; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Bauer M; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Moita LF; Instituto Gulbenkian de Ciência, Oeiras, Portugal., Helbig C; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Schlattmann P; Institute of Medical Statistics, Computer Sciences, and Data Science, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Ehler J; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Rahmel T; Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany., Meybohm P; Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany., Gründling M; Department of Anesthesiology, Greifswald, University Hospital of Greifswald, Greifswald, Germany., Schenk H; Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany., Köcher T; Vienna BioCenter Core Facilities GmbH, Wien, Austria., Brunkhorst FM; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Gräler M; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Heger AJ; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Weis S; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany sebastian.weis@med.uni-jena.de.; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.; Leibniz Institute for Infection Biology and Natural Products Research, Hans-Knöll Institute - HKI, Jena, Germany.
Corporate Authors: EPOS-1 study group, SepNetCriticalCare TrialsGroup
Source: BMJ open [BMJ Open] 2024 Apr 22; Vol. 14 (4), pp. e075158. Date of Electronic Publication: 2024 Apr 22.
Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2044-6055
DOI:10.1136/bmjopen-2023-075158